Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-B7-H3 Antibody (8G959) is an antibody targeting B7-H3. Anti-B7-H3 Antibody (8G959) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $208 | 7-10 days | |
100 μL | $349 | 7-10 days |
Description | Antibody Type: Recombinant Monoclonal Application: ELISA Reactivity: Human, Cynomolgus |
Alias | UNQ309, PSEC0249, PRO352, CD276, B7-H3, B7 homolog 3, 4Ig-B7-H3 |
Ig Type | hIgG1 |
Clone | 8G959 |
Reactivity | Human, Cynomolgus |
Verified Activity | 1. The Binding Activity of Human CD276 with Anti-CD276 recombinant antibody Activity: Measured by its binding ability in a functional ELISA. Immobilized human CD276 at 2 μg/mL can bind Anti-CD276 recombinant antibody. The EC50 is 4.299-5.373 ng/mL. 2. The Binding Activity of Human CD276 with Anti-CD276 recombinant antibody Activity: Measured by its binding ability in a functional ELISA. Immobilized human CD276 at 2 μg/mL can bind Anti-CD276 recombinant antibody. The EC50 is 47.12-54.16 ng/mL. 3. Overlay Peak curve showing MCF7 cells stained with TMAH-00187MA1HU (red line) at 1:100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-human IgG(H+L) at 1:200 dilution for 35min at 4°C.Control antibody (green line) was human IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed. |
Application | ELISA |
Recommended Dose | ELISA:1:5000-1:50000. |
Antibody Type | Monoclonal |
Subcellular Localization | Membrane; Single-pass type I membrane protein. |
Construction | Recombinant Antibody |
Purification | Affinity-chromatography |
Appearance | Liquid |
Formulation | Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, PH 7.4. |
Research Background | Earlier studies found that B7H3 (also known as B7H3) promotes the activation of T cells. Chapoval et al. confirmed that in the presence of anti-CD3 antibodies, B7H3 can promote the proliferation of CD4 and CD8+ T cells and selectively promote the secretion of IFN-γ. And B7H3 transfection into tumor cells can enhance the killing ability of CTL. Further research found that only TLT-2 transgenic cells could bind to mouse B7H3 with high affinity, and TLT-2 was determined to be the receptor molecule of B7H3. Moreover, Hashiguchi et al. confirmed that the B7H3-TLT-2 pathway enhanced T cell activation. However, Leitner et al. did not find the specific binding of B7H3 to TLT-2 by flow cytometry, therefore, the exact receptor molecule of B7H3 is still unclear. On the other hand, studies have found that B7H3 can also suppress T-cell immune responses. Some studies have shown that B7H3 can inhibit human and mouse T cells by activating or inhibiting NFTA (nuclear factor for activated T cells), NF-KB (nuclear factor kB) and AP-1 (activator protein-1) pathways. activation. In addition, results have demonstrated that B7H3 may inhibit T cell immune responses by inhibiting the activity of Thl. The study of Leiner et al. also found that B7H3 can down-regulate the secretion of IL-2 in T cells to inhibit the activity of T cells. |
Conjucates | Unconjugated |
Immunogen | Recombinant Protein: Human CD276 Protein |
Antigen Species | Human |
Gene ID | 80381 |
Uniprot ID | |
Biology Area | Cancer, Immunology, Stem cells |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.